LeonaBio (LONA) Amortizatization of Intangibles (2019 - 2026)
LeonaBio (LONA) posted quarterly Amortizatization of Intangibles of $260000.0 for Q1 2026, up 300.0% year-over-year from $65000.0 in Q1 2025, and up 288.06% quarter-over-quarter from $67000.0 in Q4 2025.
LeonaBio (LONA) Amortizatization of Intangibles (2019 - 2026) Analysis & Trends
LeonaBio (LONA) has reported Amortizatization of Intangibles for 8 consecutive years, with $260000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortizatization of Intangibles rose 300.0% year-over-year to $260000.0; the TTM figure through Mar 2026 stood at $524000.0 (up 66.88% YoY), while the FY2025 annual figure was $329000.0, down 36.12% from the prior year.
- Amortizatization of Intangibles climbed to $260000.0 in Q1 2026 per LONA's latest filing, from $67000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $406000.0 in Q2 2023 and bottomed at -$140000.0 in Q1 2022.
- Historically, Amortizatization of Intangibles has averaged $172941.2 across 5 years, with a median of $165000.0 in 2024.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles surged 4611.11% — and 2024, when it sank 90.46%.
- LeonaBio's Amortizatization of Intangibles stood at $355000.0 in 2022, then retreated by 20.28% to $283000.0 in 2023, then tumbled by 90.46% to $27000.0 in 2024, then surged by 148.15% to $67000.0 in 2025, then surged by 288.06% to $260000.0 in 2026.
- Business Quant data shows LONA's Amortizatization of Intangibles at $260000.0 in Q1 2026, $67000.0 in Q4 2025, and $70000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | LeonaBio | 180.91 Mn | 129.85 Mn | - | 228,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 260,000.00 |
| Mar 31, 2026 | 260,000.00 |
| Dec 31, 2025 | 67,000.00 |
| Dec 31, 2025 | 67,000.00 |
| Sep 30, 2025 | 70,000.00 |
| Sep 30, 2025 | 70,000.00 |
| Jun 30, 2025 | 127,000.00 |
| Jun 30, 2025 | 127,000.00 |
| Mar 31, 2025 | 65,000.00 |
| Mar 31, 2025 | 65,000.00 |
| Dec 31, 2024 | 27,000.00 |
| Dec 31, 2024 | 27,000.00 |
| Sep 30, 2024 | 57,000.00 |
| Sep 30, 2024 | 57,000.00 |
| Jun 30, 2024 | 165,000.00 |
| Jun 30, 2024 | 165,000.00 |
| Mar 31, 2024 | 266,000.00 |
| Mar 31, 2024 | 266,000.00 |
| Dec 31, 2023 | 283,000.00 |
| Dec 31, 2023 | 283,000.00 |